Literature DB >> 11814498

Prostaglandin E2 gel versus misoprostol for cervical ripening in patients with premature rupture of membranes after 34 weeks.

W Eric Frohn1, Stephanie Simmons, S J Carlan.   

Abstract

OBJECTIVE: To compare intravaginal misoprostol to prostaglandin (PG) E2 for cervical ripening in women with premature rupture of the membranes (PROM) after 34 weeks of gestation.
METHODS: Women with PROM after 34 weeks of gestation and an unripe cervix were randomized to receive PGE2 (2.5 mg) or misoprostol (50 microg). Both agents were placed intravaginally immediately after randomization, and the dose was repeated 6 hours later if necessary. After another 6 hours from the second insertion, oxytocin treatment was started if labor had not begun. Forty patients in each group were required to show a 30% improvement in delivery within 12 hours in the misoprostol group.
RESULTS: One hundred nine patients were randomized; 54 were assigned to misoprostol and 55 to PGE2. Important demographic and clinical characteristics were similar between the groups. The mean time from first insertion to delivery was 16.4 hours in the misoprostol group and 22.0 hours in the PGE2 group. A second dose was required less frequently in the misoprostol group (22% vs 62% in the PGE2 group), and the percentage of patients delivered within 12 hours was higher in the misoprostol group (41% vs 16%). Tachysystole occurred in 20% and 6% of women in the misoprostol and PGE2 groups, respectively. Hyperstimulation occurred in 9% and 0%, and cesarean delivery in 19% and 26% of women in the misoprostol and PGE2 groups, respectively. Neonatal outcome was similar between groups.
CONCLUSION: Intravaginal misoprostol is more effective than local PGE2 application to treat PROM after 34 weeks of gestation, but tachysystole occurs more commonly with misoprostol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814498     DOI: 10.1016/s0029-7844(01)01677-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

Review 1.  Vaginal misoprostol for cervical ripening and induction of labour.

Authors:  G Justus Hofmeyr; A Metin Gülmezoglu; Cynthia Pileggi
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women.

Authors:  Dulce Hernández-Hernández; María Vargas-Rivera; Alejandro A Nava-Ocampo; José Palma-Aguirre; Héctor Sumano-López
Journal:  BMC Pregnancy Childbirth       Date:  2002-04-05       Impact factor: 3.007

Review 3.  A novel misoprostol delivery system for induction of labor: clinical utility and patient considerations.

Authors:  Megan L Stephenson; Deborah A Wing
Journal:  Drug Des Devel Ther       Date:  2015-04-22       Impact factor: 4.162

4.  Comparative study of dinoprostone and misoprostol for induction of labor in patients with premature rupture of membranes after 35 weeks.

Authors:  Flavie Sire; Laure Ponthier; Jean-Luc Eyraud; Cyrille Catalan; Yves Aubard; Perrine Coste Mazeau
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

5.  MANAGEMENT OUTCOME OF PREMATURE RUPTURE OF MEMBRANES IN A TERTIARY HEALTH FACILITY IN SOUTH WESTERN NIGERIA.

Authors:  B K Suleiman; O O Bello; A M Tijani; T A O Oluwasola
Journal:  Ann Ib Postgrad Med       Date:  2021-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.